Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Phase I/II Dose-Escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Clinical Trial Details

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 leads to treatment response.
This research study is being done because the standard treatments for prostate cancer that has spread beyond the prostate gland are intended to minimize the adverse effects of the disease and make men live longer. These treatments, however, are not curative so additional treatments are needed.
Prostate-specific membrane antigen (PSMA) is a protein that is on the surface of most prostate cancer cells. It is absent from most other normal places in the body, but is present to a lower degree in the kidney, small intestine, salivary glands, and brain. J591 is a monoclonal antibody (an engineered protein) which recognizes PSMA. Actinium-225 (225Ac) is a small radioactive particle that emits alpha-particles (damaging/ionizing radiation). 225Ac-J591 is the combination compound that has the radioactive particle linked to J591. It is designed so that J591 will recognize PSMA and drags the radioactive particle 225Ac with it wherever it goes. This drug is used not FDA approved for any indication and is considered experimental.

Key Eligibility: 

Inclusion Criteria:

  1. Histologically or cytologically confirmed adenocarcinoma of prostate

  2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:
    • PSA progression
    • Objective radiographic progression in soft tissue
    • New bone lesions

  3. ECOG performance status of 0-2

  4. Have serum testosterone <50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they have not undergone orchiectomy.

  5. Have previously been treated with at least one of the following in any disease state:
    • Androgen receptor signaling inhibitor (such as enzalutamide)
    • CYP 17 inhibitor (such as abiraterone acetate)
  6. Have previously received taxane chemotherapy (in any disease state),been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.

  7. Age >18 years

  8. Patients must have normal organ and marrow function 

Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan


June Greenberg, RN
(212) 746-2651


Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group